Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604229 | 0.92 | CACNA1G (0.54) | KMT2AALDH1A1TSHRHTR7HTR1A | |
| SCHEMBL7423981 | 0.91 | HTR7 (0.57) | KMT2AALDH1A1TSHRHTR7SIGMAR1 | |
| SCHEMBL7422666 | 0.89 | HTR7 (0.58) | ALDH1A1HTR7SIGMAR1OPRM1KDM4E | |
| SCHEMBL7423471 | 0.89 | HTR7 (0.58) | ALDH1A1HTR7SIGMAR1OPRM1KDM4E | |
| SCHEMBL1206024 | 0.89 | SMN1; SMN2 (0.54) | KMT2AALDH1A1KDM4E | |
| SCHEMBL2085619 | 0.89 | SMN1; SMN2 (0.54) | KMT2AALDH1A1KDM4E | |
| SCHEMBL10898699 | 0.88 | ADRA1D (0.53) | KMT2AALDH1A1SIGMAR1OPRM1HRH3 | |
| SCHEMBL11632873 | 0.87 | ALDH1A1 (0.56) | KMT2AALDH1A1TSHRHTR7SIGMAR1 | |
| Hydrochloric Acid SCHEMBL10899218 | 0.87 | ALDH1A1 (0.55) | KMT2AALDH1A1SIGMAR1OPRM1HRH3 | |
| SCHEMBL4083554 | 0.85 | LMNA (0.60) | KMT2AALDH1A1TSHRSIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383772-B1 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2006-08-30 | — | — | EP | disclosed |
| CN-1246323-C | Nitrogen-based camptothecin derivatives | CALIFORNIA PACIFIC MED CENTER (US) | 2006-03-22 | — | — | CN | disclosed |
| US-6933302-B2 | Nitrogen-based homo-camptothecin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-08-23 | — | — | US | disclosed |
| US-6855720-B2 | Nitrogen-based camptothecin derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-02-15 | — | — | US | disclosed |
| US-6825207-B2 | ANTICANCER AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| CN-1511159-A | Nitrogen-based camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-07-07 | — | — | CN | disclosed |
| US-20040063740-A1 | For treatment of cancer | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-04-01 | — | — | US | disclosed |
| EP-1383772-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003101998-A1 | NITROGEN-BASED HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-04-17 | — | — | US | disclosed |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | US ARMY, SECRETARY OF THE ARMY | 2003-02-13 | — | — | US | disclosed |
| WO-2002070525-A2 | NITROGEN-BASED CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-09-12 | — | — | WO | disclosed |
| US-6403604-B1 | ANTITUMOR | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063740-A1 | For treatment of cancer | MGMT, PAICS, DCK | KMT2A 2430/4885ALDH1A1 1708/4885TSHR 4326/4885 |
| US-20030073698-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | KMT2A 2819/4885ALDH1A1 1488/4885TSHR 3983/4885 |
| US-20030032624-A1 | Nitrogen-based camptothecin derivatives | DCK, NEK11, NME1 | KMT2A 2819/4885ALDH1A1 1488/4885TSHR 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.